Clinical Trial Update: Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating immune function and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)
• Natalizumab (natalizumab)

Snippet

Sponsor: University Hospital Muenster | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 4 | Status: UNKNOWN